← All Calidi Biotherapeutics, INC filings

Calidi Biotherapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

AMEX
CLDI
Calidi Biotherapeutics, INC
10-K: Calidi Biotherapeutics Faces Going Concern Doubt Amidst Losses
Calidi Biotherapeutics reported significant losses and expressed substantial doubt about its ability to continue as a going concern, despite advancing its RedTail platform and securing recent financings.
AMEX
CLDI
Calidi Biotherapeutics, INC
10-K: Calidi Biotherapeutics Reports on Capital Structure, Clinical Programs in Annual 10-K Filing
Calidi Biotherapeutics outlines its capital structure, clinical trial progress, and regulatory landscape in its annual 10-K filing, highlighting both opportunities and challenges for its novel immuno-oncology platforms.
AMEX
CLDI
Calidi Biotherapeutics, INC
10-K: Calidi Biotherapeutics Outlines Capital Structure and Growth Strategy in 10-K Filing
Calidi Biotherapeutics details its capital structure, stock options, warrants, and strategic plans for advancing its immuno-oncology pipeline in its annual 10-K filing.